The invention provides humanized antibodies binding to CLDN18.2 with a high affinity. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.

Provided herein are methods of determining product quality of an antibody composition, wherein the ADCC activity level of the antibody composition is a criterion upon which product quality of the antibody composition is based. In exemplary embodiments, the method comprises (i) determining the total afucosylated (TAF) glycan content of a sample of an antibody composition; and (ii) determining the product quality as acceptable and/or achieving the ADCC activity level criterion when the TAF glycan content determined in (i) is within a target range. Related methods of monitoring product quality and methods of producing an antibody composition are further provided herein.

The present invention provides an anti-TIGIT immunosuppressant and use thereof. The immunosuppressant can bind to the extracellular region of human TIGIT, and can be used for treating diseases such as a cancer.

The present inventions provide methods to control the heterogeneity of Fc-containing proteins, such as antibodies produced in cell culture, particularly mammalian cell culture by controlling culture pCO.sub.2, as well as products produced by these methods. Among other things, the inventions provide for lowering the percentage of acidic charge variants in antibody products. Proteins that comprise Fc moieties include but are not limited to Fc-containing proteins, such as antibodies and antibody derivatives, and fragments of both.

This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

The invention describes antibodies or functional parts, derivatives and/or analogues thereof that comprise a variable domain that binds an extracellular part of EGFR and a variable domain that binds an extracellular part of LGR5 for use in the treatment of cancer wherein the antibody or functional part, derivative and/or analogue thereof is administered with a topoisomerase I inhibitor.